Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

(2015) D. Chu et al.   CLINICAL CANCER RESEARCH

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

(2015) Matthew J. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

(2015) Rinath Jeselsohn et al.   Nature Reviews Clinical Oncology

Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer

(2014) Costanza Paoletti et al.   CLINICAL CANCER RESEARCH

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Circulating Tumor Cells: Liquid Biopsy of Cancer

(2012) C. Alix-Panabieres et al.   CLINICAL CHEMISTRY

Biospecimen Reporting for Improved Study Quality (BRISQ)

(2011) Helen M. Moore et al.   JOURNAL OF PROTEOME RESEARCH

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

(2010) S-J Dawson et al.   BRITISH JOURNAL OF CANCER

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY